Last updated on October 2018

Safety Tolerability PK and PD of Posiphen in Subjects With Early Alzheimer's Disease

Brief description of study

This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).

Detailed Study Description

Posiphen, which was discovered by the US National Institute on Aging (NIA) is a small, orally active, experimental drug that specifically inhibits the synthesis of amyloid precursor protein (APP), Tau and -Synuclein. It is distinct from other Alzheimer's disease drugs currently in development, because it inhibits the formation of several toxic proteins, rather than removing individual toxic protein after they are produced. Posiphen has potential utility as a disease modifying treatment for AD. The present study will confirm the pharmacokinetics (PK) of Posiphen and its metabolites in plasma and cerebral spinal fluid (CSF). It will also measure the effects of a 23-25 day treatment period with Posiphen on the CSF and plasma levels of a number of biomarkers, inflammatory factors and control proteins. It will also expand the safety data in humans by extending the treatment period from 10 days to a treatment period from 23-25 days. In addition, this study will measure concentrations of various soluble biomarkers in CSF and use the SILK assay methods to directly measure the effect of Posiphen on the fractional synthesis rate of A40 in CSF, which will help guide the further development of Posiphen and determine the feasibility of SILK in a multicenter trial.

Clinical Study Identifier: NCT02925650

Contact Investigators or Research Sites near you

Start Over

Daniel Szpak, RN

UCSD Alzheimer's Disease Research Center
La Jolla, CA United States
  Connect »

Stephanie Fritz, RN, BSN

IU Health Partners, Adult Neurology Clinic
Indianapolis, IN United States
  Connect »

Jill Boyd

Washington University Sleep Medicine Center
Brentwood, MO United States
  Connect »

Jackie Darrow

Johns Hopkins Hospital
Baltimore, MD United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.